Featured Content

Ponatinib: Black Box Warning and Drug Interactions

If a patient develops any adverse event while on ponatinib, clinicians should perform a risk-benefit analysis before deciding whether to continue treatment.

TKI Discontinuation and Chronic Myeloid Leukemia

TKIs offer the possibility of durable responses for patients with CML, though it is unclear whether discontinuation is feasible.

Vitamin D and Cancer: An Unclear Relationship

According to the National Cancer Institute, there are not enough available data to establish whether taking vitamin D can prevent cancer.

Basket Trials: Advantages and Limitations

Basket trials offer a cost-effective option to evaluate targeted agents in multiple malignancies, but it is important to be aware of their limitations.

The Dashboard of Happiness

Dr Barbara Burtness of Yale University's School of Medicine discusses the relationship between happiness and clinical practice in oncology.

Chronic Myeloid Leukemia Resources

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters